Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable insulin Clear all
Completed Phase 4 Interventional Results available

Detemir: Role in Type 1 Diabetes

NCT00564395
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 1 Interventional

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00438321
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Zoladex, Testosterone gel, Anastrozole Pill, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 2 Interventional Results available

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

NCT00572156
View directory record Official record
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Early Phase 1 Interventional

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

NCT03400501
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Degludec, Insulin Glargine
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion

NCT02906891
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Vigilant Diabetes Management Application
Device
Lead sponsor
InSpark Technologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional Results available

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

NCT02558491
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Decision Support System, Usual Care
Device · Other
Lead sponsor
Daniel Chernavvsky, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

NCT00487240
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro Protamine Suspension, Insulin Levemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Idaho Falls, Idaho • Springfield, Illinois • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

NCT07287943
View directory record Official record
Conditions
Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I
Interventions
Medtronic 780G AID
Device
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

Insulin Glargine "All to Target" Trial

NCT00384085
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glulisine, Insulin Glargine, Premixed Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 80 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2011 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

NCT02738151
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

NCT00046501
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
9 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

NCT03095651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Results available

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

NCT04279613
View directory record Official record
Conditions
Type I Diabetes
Interventions
NNC0361-0041, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness

NCT00530023
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Loma Linda, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

NCT01755416
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

NCT00356109
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

NCT02527265
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Afrezza
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3209590 in Participants With Type 1 Diabetes

NCT04450407
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY3209590, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Concord, California • Fresno, California • Ventura, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

NCT00502138
View directory record Official record
Conditions
IDDM
Interventions
Continuous Pramlintide infusion
Drug
Lead sponsor
University Diabetes & Endocrine Consultants
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 4 Interventional Results available

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

NCT00283049
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Insulin Glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2011 · Synced Oct 23, 2026, 4:46 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

NCT05985135
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Muscle Biopsy, Jell-O with Amino acids, Dextrose
Procedure · Other · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 4:46 AM EDT